Find all the latest information
, arranged by types, translocations, and mutations.
Listed below are recently updated categories.
Coupling germline genetics to interferon-alpha responses in polycythemia vera treatment
Pegylated interferon alfa-2 (PEG-IFN) induces high response rates in many patients with polycythemia vera (PV),...
Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms
The bone marrow niche is the local tissue microenvironment that maintains and regulates stem...
The long-term efficacy of interferon alpha in targeting different driver mutations involved in MPN
Mutations in JAK2V617F, calreticulin (CALR), and thrombopoietin receptor (MPL) genes are three main...
Curative role of allogeneic hematopoietic stem cell transplantation in patients with myeloproliferative neoplasm, unclassifiable
Myeloproliferative neoplasm, unclassifiable (MPN-U) is a heterogeneous...
Calreticulin haploinsufficiency is needed for the induction of MPN-like pathology in vitro
Mutant CALR has been shown to bind to MPL and activate downstream signaling pathways that lead to the...
Promising preclinical data on selective HDAC11 inhibition and MPN improvement
During the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (2019), Vasundhara Sharma presented...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with...
Increased a5β1 integrin adhesion to fibronectin contributes to megakaryocytosis in primary myelofibrosis models
Shinobu Matsuura and colleagues investigated the role of fibronectin and its main...
Epigenetic modifier mutations
JAK2 driver mutations
JAK2 exon 12 deletions
JAK2 exon 12 insertions
MPL driver mutations
Chronic eosinophilic leukemia
Chronic neutrophilic leukemia
Tumor suppressor mutations